Johnson & Johnson

News

Sanofi's Sarclisa gets one up on rival Darzalex in myeloma

Sanofi's Sarclisa has been an also-ran in the anti-CD38 antibody class behind Johnson & Johnson and Genmab's blockbuster Darzalex, but now has a chance to steal some of the spotlight.

News

J&J tries to push talc bankruptcy over the line once again

Johnson & Johnson's long-running effort to put litigation claiming its talc products caused cancer has continued with a third attempt to place a subsidiary company into bankruptcy.

News

J&J nets another key approval for blockbuster hope Rybrevant

Johnson & Johnson's target of $5 billion in sales for its EGFRxMET bispecific antibody Rybrevant has moved a step closer, after a new FDA approval in non-small cell lung cancer (NSCLC).

News

ESMO: J&J cues up phase 3 for Rybrevant in colorectal cancer

Johnson & Johnson is planning a phase 3 programme for Rybrevant in colorectal cancer as a follow-up to its first indication in non-small cell lung cancer (NSCLC), after reporting encour

News

J&J sweetens controversial talc settlement deal

In a bid to put litigation over the safety of its talc products into the rearview mirror, Johnson & Johnson has added another $1.1 billion to its settlement offer, according to media re

News

J&J launches gMG market bid with nipocalimab filing

Johnson & Johnson has submitted its first marketing application for nipocalimab, seeking approval for the FcRn blocker in generalised myasthenia gravis (gMG), where it would compete wit

Sanofi's Sarclisa gets one up on rival Darzalex in myeloma

J&J tries to push talc bankruptcy over the line once again

J&J nets another key approval for blockbuster hope Rybrevant

ESMO: J&J cues up phase 3 for Rybrevant in colorectal cancer

J&J sweetens controversial talc settlement deal

J&J launches gMG market bid with nipocalimab filing

Lilly bags FDA okay for Wegovy pill rival orforglipron

Using AI-driven synthetic personas to take your insights fur...

Johnson & Johnson

Editor's Picks